Monkeypox virus: past and present.

Background: The objective of this paper is to analyze the current status of monkeypox worldwide. In the face of this public health threat, our purpose is to elucidate the clinical characteristics and epidemiology of monkeypox, the developmental progress of monkeypox-related drugs and the vaccines available.

Data Sources: The literature review was performed in databases including PubMed, Science Direct and Google Scholar up to July 2022.

[The high expression of HPV31 and 52 L2 fusion protein in E. coli and detection of its immunogenicity].

Objective: To express HPV31 and 52 L2 fusion protein and detect its immunogenicity.

Methods: According to the amino acid sequences of HPV31 and 52 L2 11-200AA published in the GenBank database, weartificially synthesized the HPV31 and 52 L2 fusion gene which was optimized according to Escherichia coli codon usage and encodes 11-200 amino acid of HPV31 and HPV52 L2, then cloned it into pET-9a vector. The HPV31 and 52 L2 fusion protein was expressed in Prokaryotic expression system and the mice were immunized with the fusion protein after purification.

[High expression of HPV16L2N120E7E6 fusion protein in E. coli and its inhibitory effect on tumor growth in mice].

Objective: To investigate the high expression of HPV16L2N120E7E6 fusion protein by prokaryotic expression system, and evaluate its immunogenicity and antitumor efficacy in vaccinated mice.

Methods: The HPV16L2N120E7E6 fusion gene, its codons were optimized to increase the expression of the protein, was constructed by overlap extension PCR and inserted into prokaryotic expression vector pET9a. Then the fusion protein was expressed by inducing with IPTG in E.

[Identification specific T lymphocyte epitopes on E6 protein of human papillomavirus type 18 in mice].

Objective: To identify specific T lymphocyte epitope on E6 protein of human papillomavirus type 18 in mice.

Methods: Infection with one recombinant vaccinia virus rVVJ18 E7, E6 respectively in C57 BL/6 and BALB/c mice, specific cellular immune responses were detected by ELISPOT or intracellular cytokine stainings by using a series of overlapping synthetic peptides covering full length of the amino acid sequence of E6 and E7 proteins or various truncated peptides.

Results: The rVVJ18 E7, E6 generated significant E6 specific T-cell immune responses in vaccinated mice.

[The expression and preliminary evaluation of HPV6bL2deltaN360E7E6 fusion protein in E. coli for genital warts].

Objective: To express HPV6bL2deltaN360E7E6 fusion protein in E. coli and preliminarily evaluate its immune effect.

Methods: Three HPV6b gene fragments, which were L2(1-360 bp), E7 and E6, were fused by overlapping PCR, then were inserted into a prokaryotic expression vector and expressed in E.

[Construction of recombinant vaccinia virus expressing HPV18E7E6 fusion proteins and detection of its immunogenicity in mice].

Objective: To construct one recombinant vaccinia virus expressing the HPV18 E6 and E7 fusion proteins as HPV18 therapeutic vaccine candidate, and test its immunogenicity.

Methods: The fusion E7E6 genes were synthesized and mutated to inactivate their oncogenic potential, and inserted into a vaccinia virus plasmid vector to construct one recombinant vaccinia virus. Finally its immunogenicity was characterized in immunized mice.

[Highly efficient expression of codon-optimized human papillomavirus 16 L2E7 gene in Escherichia coli].

Objective: To enhance the expression level of human papillomavirus (HPV) 16 L2E7 in Escherichia coli (E. coli), in aim of providing high-level expression of HPV16 L2E7 strain for pre-clinical high-throughout production.

Methods: The whole L2E7 gene was optimized by software of Synthetic Gene Designer, reflecting E.

[Prokaryotic expression and purification of human papillomavirus type 11 L2E7 fusion protein vaccine and its immunnogenicity].

Objective: To construct the Escherichia coli (E. coli) prokaryotic expression system pET9aHPV11L2E7, purify the fusion protein L2E7 and study the immunnogenicity of the protein.

Methods: The HPV11 L2, E7 coding region was amplified from condyloma acuminata tissue specimen by PCR.

[Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].

Background: Many epidemiological and experimental evidences prove that cervical cancers are strongly associated with genital high-risk types of human papillomavirus (HPV). HPV16 is present in 50% of the tumor specimens. Thus, it is important to develop vaccines against HPV16 and cervical cancer.

[Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].

Objective: To generate a human papillomavirus (HPV16) prophylactic and therapeutic vaccine candidate for cervical cancer.

Methods: HPV16 major capsid protein L1 gene/minor capsid protein L2 gene and HPV16 early E6/E7 genes were inserted into a vaccinia virus expression vector. A strain of non-recombinant vaccinia virus containing the sequences was obtained through a homologous recombination and identified.

[Construction of recombinant vaccina virus of HPV16 and its antitumor effect].

Background & Objective: Cervical cancer is tightly related with high-risk types of human papillomavirus (HPV), among which HPV16 is most common. This study was to construct HPV16 L1, L2, E67 coexpression non-replication vaccina virus, and explore its immunization effects.

Methods: HPV16 major capsid protein L1/L2 genes and HPV16 early E6/E7 genes were inserted into a vaccina virus expression vector to construct recombinant vaccina virus NTVJE67CKL1L2 by homologous recombination; the recombinant virus was identified by DNA hybridization and Western blot.

[Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice].

Objective: To investigate the anti-tumor immunity of the non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins.

Methods: C57BL/6 mice were immunized by non-replicating recombinant vaccinia virus (NTVJmE6E7), and then specific CTLs were determined. Immune protection effects were evaluated by challenges of different doses of TC-1 tumor cells.